RINGPU(SZ:300119)2023-04-04 09:10Group 1: Financial Performance - In 2022, the company achieved a revenue of 208,425.04 million CNY, representing a year-on-year growth of 3.84% [3] - The net profit attributable to the parent company was 34,669.87 million CNY, a decrease of 16.01% compared to the previous year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 28,071.54 million CNY, down by 1.37% year-on-year [3] Group 2: Production and Capacity Expansion - The company completed several capacity expansion projects, including the "New GMP Upgrade and Expansion Project" and "Natural Plant Industry Base," significantly increasing production capacity [3] - The new raw material drug factory of Longxiang Pharmaceutical began trial production in March 2022, with full capacity expected to be released in 2023 [6] Group 3: Research and Development - In 2022, the company obtained 8 new veterinary drug registration certificates and 35 patent technologies, achieving a record high in new veterinary drug registrations [3] - R&D investment increased by 11% in 2022, focusing on high-end talent recruitment and the "independent R&D + joint tackling" model [6] Group 4: Market Strategy and Product Development - The company plans to launch several new products in 2023, including vaccines for pigs and pets, enhancing its product matrix [7] - The pet segment revenue doubled in 2022, with a focus on expanding strategic cooperation with major clients in 2023 [4] Group 5: Strategic Partnerships - The company announced a strategic partnership with Shengnong Development and Shengwei Biological, aiming to enhance R&D capabilities and expand sales channels [5] - The collaboration will establish a poultry disease prevention research institute and a disease monitoring and early warning platform [5]